| Tumor clone dynamics in lethal prostate cancer S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ... Science translational medicine 6 (254), 254ra125-254ra125, 2014 | 388 | 2014 |
| PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer E Castro, N Romero-Laorden, A del Pozo, R Lozano, A Medina, J Puente, ... Journal of Clinical Oncology 37 (6), 490-503, 2019 | 334 | 2019 |
| PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ... European urology 67 (4), 795-802, 2015 | 276 | 2015 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ... PloS one 12 (12), e0189848, 2017 | 262 | 2017 |
| Circulating tumor cells: a multifunctional biomarker TA Yap, D Lorente, A Omlin, D Olmos, JS de Bono Clinical Cancer Research 20 (10), 2553-2568, 2014 | 241 | 2014 |
| Visceral disease in castration-resistant prostate cancer CJ Pezaro, A Omlin, D Lorente, DN Rodrigues, R Ferraldeschi, ... European urology 65 (2), 270-273, 2014 | 237 | 2014 |
| Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone D Bianchini, D Lorente, A Rodriguez-Vida, A Omlin, C Pezaro, ... European journal of cancer 50 (1), 78-84, 2014 | 234 | 2014 |
| Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of … D Lorente, J Mateo, AJ Templeton, Z Zafeiriou, D Bianchini, ... Annals of Oncology 26 (4), 750-755, 2014 | 209 | 2014 |
| Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 201 | 2015 |
| Sequencing of agents in castration-resistant prostate cancer D Lorente, J Mateo, R Perez-Lopez, JS de Bono, G Attard The lancet oncology 16 (6), e279-e292, 2015 | 184 | 2015 |
| Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents CJ Pezaro, AG Omlin, A Altavilla, D Lorente, R Ferraldeschi, D Bianchini, ... European urology 66 (3), 459-465, 2014 | 173 | 2014 |
| Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer D Lorente, D Olmos, J Mateo, D Bianchini, G Seed, M Fleisher, DC Danila, ... European urology 70 (6), 985-992, 2016 | 160 | 2016 |
| Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant … J Welti, DN Rodrigues, A Sharp, S Sun, D Lorente, R Riisnaes, ... European urology 70 (4), 599-608, 2016 | 142 | 2016 |
| Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis K Brasso, FB Thomsen, AJ Schrader, SC Schmid, D Lorente, M Retz, ... European urology 68 (2), 317-324, 2015 | 134 | 2015 |
| Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study R Perez-Lopez, J Mateo, H Mossop, MD Blackledge, DJ Collins, M Rata, ... Radiology 283 (1), 168-177, 2016 | 104 | 2016 |
| A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer R Venkitaraman, D Lorente, V Murthy, K Thomas, L Parker, R Ahiabor, ... European urology 67 (4), 673-679, 2015 | 104 | 2015 |
| Switching and withdrawing hormonal agents for castration-resistant prostate cancer D Lorente, J Mateo, Z Zafeiriou, AD Smith, S Sandhu, R Ferraldeschi, ... Nature Reviews Urology 12 (1), 37, 2015 | 95 | 2015 |
| The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials R Kumar, E Geuna, V Michalarea, M Guardascione, U Naumann, ... British journal of cancer 112 (7), 1157-1165, 2015 | 91 | 2015 |
| Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers J Cortes, K Tamura, DJ DeAngelo, J De Bono, D Lorente, M Minden, ... British journal of cancer 118 (11), 1425, 2018 | 90 | 2018 |
| First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate … D Bianchini, A Omlin, C Pezaro, D Lorente, R Ferraldeschi, D Mukherji, ... British journal of cancer 109 (10), 2579, 2013 | 90 | 2013 |
